GO:0060158 phospholipase C-activating dopamine receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060158 describes a G protein-coupled receptor signaling pathway that begins with dopamine binding to its receptor and ends with phospholipase C activation and regulation of downstream cellular processes such as transcription.
• This pathway is distinct from canonical cAMP-mediated dopamine signaling because it specifically couples dopamine receptors to phospholipase C and calcium signaling.
• Key molecular players include dopamine receptors (DRD1, DRD2, DRD5), G proteins (GNAQ, GNA11), phospholipase C isoforms (PLCB1, PLCB4), and downstream effectors such as IP3 receptors and protein kinase C.
• Dysregulation of phospholipase C-activating dopamine receptor signaling has been implicated in neuropsychiatric disorders, endocrine abnormalities such as hyperprolactinemia, and metabolic conditions including gestational diabetes mellitus.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of individual pathway components in disease.
• Understanding this pathway supports drug discovery, biomarker identification, and precision medicine approaches for dopamine-related disorders.
Description
The phospholipase C-activating dopamine receptor signaling pathway (GO:0060158) is a biological process in which dopamine binds to its receptor on the surface of a target cell, triggering a G protein-coupled receptor signaling cascade that activates phospholipase C and ultimately regulates downstream cellular processes, including transcription. This pathway represents a non-canonical branch of dopamine signaling that is distinct from the classical cAMP-dependent route and is critical for integrating dopamine signals into calcium and lipid second messenger systems. Researchers study this pathway because it links neurotransmitter signaling to diverse physiological outputs such as hormone regulation, neuronal plasticity, and metabolic control. Dysregulation of this pathway has been associated with hyperprolactinemia and drug-related gestational diabetes mellitus, highlighting its clinical relevance. Understanding the molecular components and regulatory mechanisms of GO:0060158 is essential for developing targeted therapeutic strategies and for interpreting pharmacovigilance data on dopamine-modulating drugs.
phospholipase C-activating dopamine receptor signaling pathway At A Glance
| GO ID | GO:0060158 |
|---|---|
| GO term | phospholipase C-activating dopamine receptor signaling pathway |
| Ontology | biological_process |
| Synonym | activation of phospholipase C activity by dopamine receptor signaling pathway; activation of phospholipase C activity by dopamine receptor signalling pathway; dopamine receptor, phospholipase C activating pathway |
| Major function | Couples dopamine binding to phospholipase C activation and downstream cellular regulation, including transcription |
| Upstream trigger | Dopamine binding to its receptor on the target cell surface |
| Key enzyme | Phospholipase C (PLC) isoforms such as PLCB1 and PLCB4 |
| Downstream effect | Regulation of downstream cellular processes, e.g. transcription |
| Associated disease examples | Hyperprolactinemia, drug-related gestational diabetes mellitus |
What Is GO:0060158?
GO:0060158 is defined as a phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. In simpler terms, it is the sequence of molecular events through which dopamine, acting via its receptor, turns on phospholipase C and thereby influences what the cell does next, including changes in gene expression.
Why Is phospholipase C-activating dopamine receptor signaling pathway Important in Cell Biology?
GO:0060158 is important because it provides a mechanistic framework for understanding how dopamine, beyond its classical cAMP-mediated actions, can activate phospholipase C and calcium signaling to modulate gene expression and cell behavior. This pathway is relevant to neuropsychiatric and endocrine disorders, as evidenced by pharmacovigilance and network pharmacology studies linking dopamine receptor modulation to hyperprolactinemia and gestational diabetes mellitus. Studying this pathway helps researchers identify drug targets, predict adverse effects, and design experiments that test causality of specific pathway components.
• Provides a non-canonical mechanism for dopamine to regulate transcription via phospholipase C and calcium.
• Links dopamine receptor activity to endocrine outcomes such as prolactin regulation.
• Implicated in drug-related metabolic disturbances including gestational diabetes mellitus.
• Offers targets for therapeutic intervention in hyperprolactinemia.
• Enables mechanistic interpretation of adverse drug reactions from pharmacovigilance databases.
• Supports the development of CRISPR models to test gene function in dopamine signaling.
• Helps distinguish pathway-specific effects from general GPCR signaling.
• Facilitates biomarker discovery for dopamine-related disorders.
• Guides precision medicine approaches for patients on dopamine-modulating drugs.
• Enhances understanding of calcium and lipid second messenger crosstalk in neurons and endocrine cells.
What Happens During phospholipase C-activating dopamine receptor signaling pathway?
Dopamine binding and receptor activation
In simple terms: Dopamine docks onto its receptor on the cell surface, switching the receptor on.
The pathway begins when dopamine binds to its receptor, a G protein-coupled receptor, on the surface of a target cell. This binding induces a conformational change in the receptor that enables it to act as a guanine nucleotide exchange factor for an associated heterotrimeric G protein. The specific dopamine receptor subtypes involved can include D1-like and D2-like receptors, depending on the cellular context.
G protein activation and phospholipase C stimulation
In simple terms: The activated receptor turns on a G protein, which then switches on the enzyme phospholipase C.
Upon receptor activation, the G protein alpha subunit exchanges GDP for GTP and dissociates from the beta-gamma dimer. The activated G alpha subunit, often of the Gq/11 family (e.g., GNAQ, GNA11), directly binds and stimulates phospholipase C isoforms such as PLCB1 and PLCB4. This step is the defining feature of GO:0060158, as it specifically leads to phospholipase C activation.
Second messenger generation and calcium release
In simple terms: Phospholipase C cuts a membrane lipid into two messenger molecules, one of which releases calcium inside the cell.
Activated phospholipase C hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to IP3 receptors on the endoplasmic reticulum, triggering the release of calcium into the cytoplasm. DAG remains in the membrane and can activate protein kinase C (PKC). These second messengers propagate the signal downstream.
Downstream regulation of transcription and cellular processes
In simple terms: The calcium and DAG signals change what genes the cell turns on or off, altering its behavior.
Elevated cytoplasmic calcium and activated PKC initiate signaling cascades that can modify transcription factors, leading to changes in gene expression. This ultimately regulates downstream cellular processes such as transcription, as stated in the GO definition. The specific transcriptional outcomes depend on the cell type and the complement of signaling molecules present.
Key Genes Involved in GO:0060158 phospholipase C-activating dopamine receptor signaling pathway
The following genes and proteins are central to the phospholipase C-activating dopamine receptor signaling pathway, based on published literature and pathway databases.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DRD1 | Dopamine receptor D1; binds dopamine and activates G proteins | Mediates D1-like dopamine signaling; target for neuropsychiatric research |
| DRD2 | Dopamine receptor D2; binds dopamine and modulates G protein signaling | Implicated in hyperprolactinemia and antipsychotic drug effects |
| DRD5 | Dopamine receptor D5; binds dopamine and activates G proteins | D1-like receptor involved in calcium signaling |
| GNAQ | Gq alpha subunit; activates phospholipase C | Key transducer linking receptor to PLC |
| GNA11 | G11 alpha subunit; activates phospholipase C | Alternative Gq/11 family member in PLC activation |
| PLCB1 | Phospholipase C beta 1; hydrolyzes PIP2 to IP3 and DAG | Central enzyme in this pathway; knockout models available |
| PLCB4 | Phospholipase C beta 4; hydrolyzes PIP2 | Isoform-specific functions in dopamine signaling |
| ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1; mediates calcium release | Downstream effector of IP3; calcium signaling research |
| ITPR2 | Inositol 1,4,5-trisphosphate receptor type 2 | Calcium release channel; tissue-specific roles |
| PRKCA | Protein kinase C alpha; activated by DAG and calcium | Phosphorylates downstream targets; transcription regulation |
| PRKCB | Protein kinase C beta; activated by DAG | Modulates neuronal and endocrine signaling |
| CALM1 | Calmodulin 1; calcium-binding protein | Relays calcium signals to downstream effectors |
| CALM2 | Calmodulin 2; calcium sensor | Regulates enzymes and ion channels in response to calcium |
| CREB1 | cAMP response element-binding protein 1; transcription factor | Integrates calcium and cAMP signals to regulate transcription |
| FOS | FBJ murine osteosarcoma viral oncogene homolog; immediate early gene | Marker of neuronal activation downstream of calcium signaling |
| JUN | Jun proto-oncogene; AP-1 transcription factor component | Mediates transcriptional responses to PKC and calcium |
| NFATC1 | Nuclear factor of activated T cells 1; calcium-regulated transcription factor | Links calcium signaling to gene expression |
How Is phospholipase C-activating dopamine receptor signaling pathway Regulated?
The phospholipase C-activating dopamine receptor signaling pathway is regulated at multiple levels. Receptor desensitization and internalization following prolonged dopamine exposure can attenuate signaling. G protein-coupled receptor kinases (GRKs) and arrestins modulate receptor activity. Phospholipase C activity itself is subject to feedback regulation by PKC-mediated phosphorylation and by calcium/calmodulin. Additionally, the pathway can be influenced by other signaling inputs that converge on calcium or DAG, such as Gq-coupled receptors for other neurotransmitters. In disease contexts, drugs such as aripiprazole can modulate dopamine receptor signaling and affect downstream prolactin regulation, as shown in network pharmacology studies. Pharmacovigilance analyses have also identified drug-related risk factors for gestational diabetes mellitus that may involve dopamine receptor signaling pathways.
phospholipase C-activating dopamine receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DRD2 | Hyperprolactinemia; antipsychotic drug response | Knockout or point-mutation cell lines to test receptor function |
| PLCB1 | Dopamine signaling dysregulation; potential neuropsychiatric phenotypes | Knockout cells to assess PLC activation and downstream transcription |
| GNAQ | Gq-mediated signaling in endocrine cells | Knock-in of constitutively active or inactive mutants |
| ITPR1 | Calcium signaling abnormalities | Overexpression or knockout to study calcium release |
| PRKCA | Transcription regulation downstream of DAG | Point mutation to alter kinase activity |
Hyperprolactinemia and dopamine receptor modulation
Hyperprolactinemia is a condition characterized by elevated prolactin levels, often resulting from dopamine receptor blockade or dysfunction. A network pharmacology and molecular docking study of aripiprazole, an antipsychotic with partial dopamine D2 receptor agonist activity, explored its pharmacological mechanism against hyperprolactinemia. The study highlighted the involvement of dopamine receptor signaling pathways, including phospholipase C-activating cascades, in regulating prolactin secretion. This suggests that GO:0060158 components may be relevant to understanding and managing drug-induced hyperprolactinemia.
Drug-related gestational diabetes mellitus
A real-world pharmacovigilance study using the FAERS database identified risk factors for drug-related gestational diabetes mellitus. While the study focused on multiple drugs, dopamine-modulating agents were among those analyzed, and signaling pathways such as phospholipase C-activating dopamine receptor signaling may contribute to metabolic dysregulation during pregnancy. This highlights the potential clinical importance of GO:0060158 in endocrine and metabolic disorders.
From phospholipase C-activating dopamine receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PLCB1 abolish dopamine-induced calcium signaling? | PLCB1 knockout cell line |
| Does a specific DRD2 mutation alter phospholipase C activation? | DRD2 point-mutation knock-in cell line |
| Can a tagged GNAQ reveal real-time G protein activation? | Tagged knock-in of GNAQ |
| Does overexpression of ITPR1 enhance calcium release? | ITPR1 overexpression cell line |
| Which genes are essential for dopamine-induced transcription? | CRISPR library screening in a dopaminergic cell model |
| Does a disease-associated variant in PRKCA affect downstream transcription? | PRKCA point-mutation knock-in |
How to Study the phospholipase C-activating dopamine receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular calcium concentration | Real-time monitoring of IP3-mediated calcium release |
| IP3 assay | Inositol 1,4,5-trisphosphate levels | Quantifying phospholipase C activity |
| PIP2 hydrolysis assay | Phosphatidylinositol 4,5-bisphosphate consumption | Measuring PLC enzymatic activity |
| Luciferase reporter assay | Transcriptional activity of calcium/PKC-responsive promoters | Assessing downstream transcription |
| RNA-seq | Global gene expression changes | Identifying transcriptional targets of the pathway |
| CRISPR knockout screening | Gene essentiality for pathway function | Discovering novel regulators |
| Molecular docking | Drug-target binding interactions | Predicting pharmacological modulation |
| Pharmacovigilance data analysis | Adverse event signals | Identifying drug-related disease risks |
Calcium imaging
Calcium imaging using fluorescent indicators such as Fura-2 or genetically encoded calcium sensors allows real-time measurement of intracellular calcium changes following dopamine stimulation. This method is directly applicable to studying the second messenger step of GO:0060158.
Phospholipase C activity assays
Phospholipase C activity can be measured using PIP2 hydrolysis assays or by detecting IP3 production with radioimmunoassays or fluorescent biosensors. These assays quantify the enzymatic step central to GO:0060158.
Transcriptional reporter assays
Reporter genes driven by calcium- or PKC-responsive promoters (e.g., CRE, AP-1) can be used to monitor downstream transcriptional regulation. This links pathway activation to gene expression changes.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout or activation screens combined with RNA sequencing and bioinformatics can identify genes that modulate GO:0060158. Network pharmacology and molecular docking studies can predict drug-pathway interactions.
How CRISPR Can Be Used to Study GO:0060158 phospholipase C-activating dopamine receptor signaling pathway
Knockout
CRISPR knockout of genes such as PLCB1, GNAQ, or DRD2 can abolish specific steps of GO:0060158, allowing researchers to test causality. Knockout cell lines are valuable for confirming whether a gene is required for dopamine-induced phospholipase C activation and downstream transcription.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to alter catalytic activity of enzymes like PLCB1 or PRKCA. These models help dissect the precise molecular mechanisms of the pathway.
Knock-in
Knock-in of tagged proteins (e.g., GFP-tagged GNAQ or ITPR1) enables real-time imaging and biochemical isolation of pathway components. Knock-in of reporter genes under pathway-responsive promoters allows monitoring of transcriptional output.
Overexpression
Overexpression of receptors, G proteins, or effectors can amplify the pathway and reveal gain-of-function phenotypes. This approach is useful for studying downstream effects such as enhanced calcium signaling or transcription.
How EDITGENE Supports phospholipase C-activating dopamine receptor signaling pathway Research
Researchers studying phospholipase C-activating dopamine receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway function or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous mechanistic and translational studies.
Contact EDITGENE today to design your custom CRISPR model for phospholipase C-activating dopamine receptor signaling pathway research.
Frequently Asked Questions About phospholipase C-activating dopamine receptor signaling pathway
What is GO:0060158?
GO:0060158 is the Gene Ontology term for phospholipase C-activating dopamine receptor signaling pathway, a biological process where dopamine binding to its receptor activates phospholipase C and regulates downstream cellular processes such as transcription.
What genes are involved in phospholipase C-activating dopamine receptor signaling pathway?
Key genes include dopamine receptors (DRD1, DRD2, DRD5), G proteins (GNAQ, GNA11), phospholipase C isoforms (PLCB1, PLCB4), and downstream effectors such as ITPR1 and PRKCA.
How is phospholipase C activated by dopamine receptors?
Dopamine binding activates the receptor, which stimulates a Gq/11 protein; the activated G alpha subunit then directly binds and activates phospholipase C.
What diseases are associated with GO:0060158?
Dysregulation has been linked to hyperprolactinemia and drug-related gestational diabetes mellitus.
What are the downstream effects of phospholipase C activation?
Phospholipase C produces IP3 and DAG, leading to calcium release and PKC activation, which can regulate transcription and other cellular processes.
How can CRISPR be used to study this pathway?
CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of specific genes in the pathway.
What methods are used to measure phospholipase C activity?
Common methods include IP3 assays, PIP2 hydrolysis assays, and calcium imaging.
Is phospholipase C-activating dopamine receptor signaling the same as cAMP signaling?
No, it is a distinct non-canonical branch that specifically activates phospholipase C and calcium signaling, rather than primarily modulating cAMP.
What is the role of DRD2 in this pathway?
DRD2 can couple to Gq/11 proteins to activate phospholipase C, and it is a target for antipsychotic drugs that affect prolactin levels.
How does aripiprazole affect this pathway?
Aripiprazole, a partial D2 receptor agonist, modulates dopamine receptor signaling and has been studied for its effects on hyperprolactinemia via network pharmacology.
Conclusion
GO:0060158, the phospholipase C-activating dopamine receptor signaling pathway, represents a critical non-canonical mechanism by which dopamine influences cellular behavior and gene expression. Its components, including dopamine receptors, Gq/11 proteins, phospholipase C isoforms, and calcium signaling effectors, are implicated in endocrine and metabolic disorders such as hyperprolactinemia and gestational diabetes mellitus. Advances in CRISPR-based modeling and bioinformatics are enabling precise dissection of this pathway, offering opportunities for therapeutic target discovery and personalized medicine. Continued research into GO:0060158 will enhance our understanding of dopamine signaling in health and disease.
References
- 1. Yang L et al.. 2024. Exploring the potential pharmacological mechanism of aripiprazole against hyperprolactinemia based on network pharmacology and molecular docking.. Schizophrenia (Heidelb) 10(1):105 PMID: 39511179
- 2. Jing H et al.. 2026. Risk factors for drug-related gestational diabetes mellitus: a real-world pharmacovigilance study based on the FAERS database.. BMC Pregnancy Childbirth 26(1) PMID: 42092831
